small molecule

ZONTIVITY

VORAPAXAR SULFATE

Loss of exclusivityDecember 2027latest FDA-listed patent expiry
CompanyKEY THERAPEUTICS LLC

Drug detail

Brand nameZONTIVITY
Active ingredientVORAPAXAR SULFATE
StrengthEQ 2.08MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMay 2014
Marketing statusDISCN

Listed patents

PatentExpiresType
7304078December 2027substance, product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ZONTIVITY patent cliff — loss of exclusivity December 2027 | CliffBio